OncoWuXi 3.0: A New Upgrade Empowering Drug Development

Posted on

From Tumor Model Database to Comprehensive Pharmacology Database:

The OncoWuXi database has successfully upgraded to version 3.0, marking a significant transformation! We have not only fully optimized the interface design to enhance user experience, but we have also made substantial advancements in the functionality, depth, and breadth of the database. OncoWuXi 3.0 is committed to providing you with a comprehensive, precise, and efficient pharmacological model database platform across multiple disease domains, tailored to meet the professional needs of researchers and drug development partners.

🚀 Highlights of the Upgrade

  • Comprehensive Multi-Disease Model Coverage: OncoWuXi 3.0 now includes 12 major disease models, including cancer, metabolic diseases, autoimmune diseases, and neuropsychiatric diseases, to support your research needs.
  • Advanced Precision Search Engine: Leveraging cutting-edge technology, our new search engine allows you to accurately target specific models, accelerating your research and development process.
  • Expanded Tumor Model Database: Featuring new PDC model data, histopathology atlases, and multi-omics analysis of drug resistance models, our expanded tumor database offers a comprehensive interpretation from tissue, cellular, and molecular perspectives, thereby enhancing data utility.
  • Revamped Interface, Enhanced Experience: The website interface has been fully optimized to be more user-oriented, significantly improving your browsing experience.
  • Shared Scientific Resources: OncoWuXi 3.0 will regularly share the latest global scientific articles, conference reports, and exhibition posters, helping you stay at the cutting edge of scientific research.

We believe that OncoWuXi 3.0 will become an even more effective guide for your drug discovery research. Thank you for your continued support and trust!

🔗 Experience Now: We cordially invite you to visit the newly upgraded OncoWuXi 3.0 website to explore more exciting features and content.

Follow Us on LinkedIn Link